TRIM33 and cancer: The risk of malignancy is not uniform across all patients, and MSAs are the most powerful tool for its stratification, offering a level of precision that was unavailable when relying solely on older, less specific demographic and clinical risk factors. The presence of anti-TIF1γ antibodies confers the highest risk of all, with a probability of associated cancer that can exceed 70% in adults [10,18].